Monday, November 9, 2026

USD/CNH Went Down By Over 2% In The Last 21 Sessions

ViaNews Editorial Team

December 25, 2023

USD/CNH Went Down By Over 2% In The Last 21 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 2.07% for the last 21 sessions. At 03:07 EST on Monday, 25 December, USD/CNH (USDCNH) is $7.15.

USD/CNH's yearly highs and lows, it's 0.007% up from its 52-week low and 0% down from its 52-week high.

News about

  • According to FXStreet on Friday, 22 December, "On the flip side, weakness below the Asian session low, around the 141.90-141.85 region, will reaffirm the near-term bias and make the USD/JPY pair vulnerable to retesting sub-141.00 levels, or a multi-month low touched last week. ", "The Japanese Yen (JPY) snaps a two-day winning streak against the US Dollar (USD), allowing the USD/JPY pair to stage a goodish intraday bounce from the 141.85 area or a fresh weekly low touched during the Asian session on Friday. "
  • Usd/jpy forecast: struggle against yen - 22 December 2023. According to DailyForex on Friday, 22 December, "The USD/JPY experienced a significant drop during Thursday's trading session, primarily driven by the continuous decline in interest rates within the United States. "
  • Usd/jpy rebounds into new Friday high, aimed for 143.00. According to FXStreet on Friday, 22 December, "The pair remains constrained at the 200-day SMA rising into the 143.00 handle, and the USD/JPY is down over six percent from November's peak bids near 151.90.", "The USD/JPY set a new high for Friday at 142.66, stopping just short of the 50-hour Simple Moving Average (SMA) as the pair gets hung up on near-term resistance levels."

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com